Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: The FIELD Helsinki substudy

Diabetes Care

Volumn 33, Issue 2, 2010, Pages 215-220

  Forsblom, Carol ^a,b   Hiukka, Anne ^b   Leinonen, Eeva S ^b   Sundvall, Jouko ^c   Groop, Per Henrik ^a,b   Taskinen, Marja Riitta ^b  

^a FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CREATININE; CYSTATIN C; DIURETIC AGENT; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; MARKER; PLACEBO;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

AGED; ALBUMINURIA; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLACEBOS; PROCETOFEN; PROGNOSIS; TRIGLYCERIDES;

EID: 75149128670     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0621     Document Type: Article

References (14)

1. Watkins PJ. Cardiovascular disease, hypertension, and lipids. BMJ 2003;326:874-876
2. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206
3. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58:293-301
4. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002;62:1743-1749
5. Colhoun HM, Lee ET, Bennett PH, Lu M, Keen H, Wang SL, Stevens LK, Fuller JH. Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S46-S53
6. Cusick M, Chew EY, Hoogwerf B, Agrón E, Wu L, Lindley A, Ferris FL III; Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 2004;66:1173-1179
7. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
8. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-493
9. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002;92:536-541
10. Ansquer JC, Dalton RN, Causse E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-913
11. Field Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [ISRCTN 64783481]. Cardiovasc Diabetol 2004;3:9
12. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD III, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406
13. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children: a meta-analysis. Clin Biochem 2007;40:383-391
14. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i